| Literature DB >> 34581894 |
Ruchi Kapoor1, Ashok Kumar Saxena1, Prerna Vasudev1, Deepak Sundriyal2, Arvind Kumar3.
Abstract
Recent improvements in the therapeutic armamentarium of oncology by the addition of targeted and immunotherapeutic agents have led to an increase in the life expectancy of advanced-stage cancer patients. This has led to an increased number of patients presenting with bone metastasis and experiencing episodes of cancer-induced bone pain (CIBP). CIBP is a crippling, chronic, morbid state interfering significantly with the functional capacity and the quality of life (QoL). CIBP is characterized by a complex multifactorial pathophysiological mechanism involving tumor cells, bone cells, inflammatory microenvironment, and the neuronal tissue. It may not be possible to mitigate pain completely; therefore, the aim should be to reach the lowest possible level of pain that allows for an acceptable QoL to the patient. Multimodality approach of surgical, radiation, medical and behavioral techniques is thus recommended to manage CIBP. This review discusses the pathogenesis and pathophysiological mechanism accompanying bone metastasis and CIBP, currently approved therapies for the management of CIBP, and the future perspective.Entities:
Keywords: Bone metastasis; Cancer induced bone pain; Osteoclast inhibitors; Quality of life
Mesh:
Substances:
Year: 2021 PMID: 34581894 DOI: 10.1007/s12032-021-01587-7
Source DB: PubMed Journal: Med Oncol ISSN: 1357-0560 Impact factor: 3.064